AR-V7 as a biomarker for resistance to treatment with abiraterone/enzalutamide in three Latin American countries: a hypothetical cost-saving analysis

Background Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors such as abiraterone and enzalutamide, for which androgen recepto...

Full description

Autores:

Pacheco Orozco, Rafael Adrián
Montealegre Paez, Ana Lorena
Cayol, Federico
Martínez Gregorio, Héctor
Oliver, Javier
Frecha, Cecilia
Vaca Paniagua, Felipe
Perdomo Lara, Sandra Janneth

Tipo de recurso:

Article of journal

Fecha de publicación:

2020

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/3934

Acceso en línea:

http://hdl.handle.net/20.500.12495/3934
https://doi.org/10.1634/theoncologist.2020-0043
https://repositorio.unbosque.edu.co

Palabra clave:

Androgen receptor antagonists
Biomarkers
Cost savings
Neoplasm drug resistance
Prostatic neoplasms
Therapeutics

Rights

openAccess

License

Attribution-NonCommercial-NoDerivatives 4.0 International